Suchergebnisse - "Taylor, Peter C"

PubPharm (361)

1

Impact of filgotinib on pain control in the phase 3 FINCH studies

enthalten in: RMD open | 2024

von Taylor, P. | Kavanaugh, A. | Nash, P. | +10

ErratumIn: RMD Open. 2024 Apr 4;10(2):. - PMID 38580354

2

Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis

enthalten in: Rheumatology (Oxford, England) | 2024

von Triaille, C. | Quartier, P. | De Somer, L. | +5

3

Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

enthalten in: Rheumatology (Oxford, England) | 2024

von Taylor, P. | Choy, E. | Baraliakos, X. | +7

4

Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment : Results Of A Long-Term Study

enthalten in: Rheumatology (Oxford, England) | 2024

von Caporali, R. | Taylor, P. | Aletaha, D. | +8

5

Quality of Life and Disability in Chikungunya Arthritis

enthalten in: Current rheumatology reviews | 2024

von Amaral, J. | Taylor, P. | Weinblatt, M. | +2

6

Correction : Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate

enthalten in: Rheumatology and therapy | 2024

von Tanaka, Y. | Taylor, P. | Elboudwarej, E. | +7

ErratumFor: Rheumatol Ther. 2023 Oct;10(5):1335-1348. - PMID 37490202

7

Are TNF inhibitors still the agent of choice for RA?

enthalten in: Nature reviews. Rheumatology | 2023

von Taylor, P.

8

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs : two phase 3 randomised trials (contRAst 1 and contRAst 2)

enthalten in: Annals of the rheumatic diseases | 2023

von Fleischmann, R. | van der Heijde, D. | Strand, V. | +19

9

Teleconsultation in rheumatology : A literature review and opinion paper

enthalten in: Seminars in arthritis and rheumatism | 2023

von Avouac, J. | Marotte, H. | Balsa, A. | +7

10

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies : a phase III randomised trial (contRAst 3)

enthalten in: Annals of the rheumatic diseases | 2023

von Taylor, P. | Weinblatt, M. | McInnes, I. | +18

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[37]